AddLife AB operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AddLife AB with three other
miscellaneous service companies in Europe:
Pharma Mar SA
sales of 162.59 million Euro [US$180.05 million]
of which 67%
was Biotech Sector),
(317.85 million Euro [US$351.99 million]
of which 88%
was R&D), and
Bachem Holding AG
based in Switzerland
(282.50 million Swiss Francs [US$285.64 million]
of which 89%
was Active Pharmaceutical Ingredients).
AddLife AB reported sales of SEK 2.48 billion (US$260.87 million)
December of 2018.
increase of 6.4%
versus 2017, when the company's sales were SEK 2.33 billion.
Sales at AddLife AB have increased during each of the previous five years
(and since 2013, sales have increased a total of 174%).
Sales of Medtech saw an increase
9.6% in 2018, from
SEK 940.00 million to SEK 1.03 billion.